[go: up one dir, main page]

CY1109014T1 - Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου - Google Patents

Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου

Info

Publication number
CY1109014T1
CY1109014T1 CY20091100456T CY091100456T CY1109014T1 CY 1109014 T1 CY1109014 T1 CY 1109014T1 CY 20091100456 T CY20091100456 T CY 20091100456T CY 091100456 T CY091100456 T CY 091100456T CY 1109014 T1 CY1109014 T1 CY 1109014T1
Authority
CY
Cyprus
Prior art keywords
disorder
canterin
solvent
treatment
metabolism disorders
Prior art date
Application number
CY20091100456T
Other languages
English (en)
Inventor
Christopher Hug
Harvey F Lodish
Original Assignee
Whitehead Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute For Biomedical Research filed Critical Whitehead Institute For Biomedical Research
Publication of CY1109014T1 publication Critical patent/CY1109014T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Αυτή η εφεύρεση αναφέρεται στη χρήση πολυπεπτιδίων της Τ-καντερίνης για την διαλογή ρυθμιστών εξ' αυτών, και τη χρήση των εν λόγω ρυθμιστών για την θεραπεία διαταραχών που επιλέγονται από την ομάδα που αποτελείται από μία διαταραχή του μεταβολισμού, μία γυναικολογική διαταραχή, μία χρόνια φλεγμονή ή μια διαταραχή του ήπατος ή των νεφρών. Οι διαταραχές του μεταβολισμού που μπορούν να θεραπευθούν με τη χρήση ενός ρυθμιστή σύμφωνα με την παρούσα εφεύρεση περιλαμβάνουν παραδείγματος χάριν την παχυσαρκία, τον διαβήτη τύπου II, την αντίσταση στην ινσουλίνη, την υπερχοληστεριναιμία, την υπερλιπιδαιμία, την δυσλιπιδαιμία, το σύνδρομο Χ, την ανορεξία και την καχεξία.
CY20091100456T 2003-12-03 2009-04-23 Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου CY1109014T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52695603P 2003-12-03 2003-12-03
EP04812804A EP1701978B1 (en) 2003-12-03 2004-12-02 Use of soluble T-Cadherin for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
CY1109014T1 true CY1109014T1 (el) 2014-07-02

Family

ID=34676687

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100456T CY1109014T1 (el) 2003-12-03 2009-04-23 Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου

Country Status (18)

Country Link
US (1) US20070212686A1 (el)
EP (1) EP1701978B1 (el)
JP (1) JP2007519894A (el)
AT (1) ATE422506T1 (el)
AU (1) AU2004297914A1 (el)
CA (1) CA2546126A1 (el)
CY (1) CY1109014T1 (el)
DE (1) DE602004019451D1 (el)
DK (1) DK1701978T3 (el)
ES (1) ES2320139T3 (el)
HR (1) HRP20090119T3 (el)
IL (1) IL175862A (el)
NO (1) NO20062975L (el)
PL (1) PL1701978T3 (el)
PT (1) PT1701978E (el)
RS (1) RS50754B (el)
SI (1) SI1701978T1 (el)
WO (1) WO2005057222A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849559A1 (en) 2006-01-10 2007-07-19 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
TWI405565B (zh) 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗－骨質流失及抗－牙周附連喪失之功效
CN102378629B (zh) 2009-04-01 2016-08-17 高露洁-棕榄公司 用于口部护理组合物的抗生物膜碳酸酯化合物
TWI481870B (zh) 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記
RU2492857C2 (ru) 2009-04-01 2013-09-20 Колгейт-Палмолив Компани Соединения - производные ментола и их применение в качестве активных системных агентов и агентов для ротовой полости
GB201312010D0 (en) * 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
EP4116711A4 (en) * 2020-03-03 2024-04-10 Tatsuya Sawamura ADIPONECTIN QUANTIFICATION METHOD AND ANALYTICAL REAGENT FOR USE IN SAID METHOD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1023445B1 (de) * 1997-10-15 2005-08-17 Pharis Biotec GmbH Cadherin derived growth factor und seine verwendung
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
JP2003523192A (ja) * 2000-02-18 2003-08-05 ビオヴィトルム・アクチボラゲット Ｆｏｘｃ２を発現する肥満のトランスジェニック動物モデル
AU2001292658A1 (en) * 2000-09-13 2002-03-26 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
AU2002240892A1 (en) * 2001-01-02 2002-07-16 Centre National De La Recherche Scientifique Protein-protein interactions in adipocyte cells
WO2004096272A2 (en) * 2003-04-29 2004-11-11 Cytos Biotechnology Ag Methods and compositions for modulating the interaction between adiponectin and its receptor
WO2005049861A2 (en) * 2003-11-10 2005-06-02 Epigenomics Ag Method for the analysis of gynaecological cell proliferative disorders

Also Published As

Publication number Publication date
JP2007519894A (ja) 2007-07-19
HRP20090119T3 (en) 2009-04-30
RS50754B (sr) 2010-08-31
AU2004297914A1 (en) 2005-06-23
WO2005057222A3 (en) 2006-02-23
EP1701978A2 (en) 2006-09-20
ES2320139T3 (es) 2009-05-19
CA2546126A1 (en) 2005-06-23
US20070212686A1 (en) 2007-09-13
WO2005057222A2 (en) 2005-06-23
PL1701978T3 (pl) 2009-07-31
ATE422506T1 (de) 2009-02-15
NO20062975L (no) 2006-06-26
PT1701978E (pt) 2009-03-03
SI1701978T1 (sl) 2009-08-31
EP1701978B1 (en) 2009-02-11
IL175862A0 (en) 2006-10-05
DK1701978T3 (da) 2009-04-06
IL175862A (en) 2010-11-30
DE602004019451D1 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
CY1109014T1 (el) Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου
NO20035526D0 (no) Forbindelser for behandling av metabolske forstyrrelser
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DE602006010408D1 (de) Blindes versehen von audiosignalen mit wasserzeichen durch verwendung von phasenmodifikationen
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2009003611A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y metodos de uso.
DK1732949T3 (da) Fremgangsmåder til behandling af smerter ved knoglekræft ved indgivelse af en nervevækstfaktorantagonist
DE60310731D1 (de) Neue, von noraporphin abgeleitete moleküle
EP1593275A4 (en) MOBILE NETWORK COMPRISING ENTITIES OF MULTIMEDIA IP SUBSYSTEMS (IMS) AND SOLUTIONS FOR SIMPLIFYING OPERATIONS AND COMPATIBILITY BETWEEN DIFFERENT IMS ENTITIES
DE502006009413D1 (de) Quervernetzte polymere, diese enthaltende galvanisierungsbäder sowie deren verwendung
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DE602006006625D1 (de) Positive lichtempfindliche isolierende Harzzubereitung, ausgehärtetes Produkt davon, sowie elektronisches Bauteil
DK1551860T3 (da) Glukokortikoid-receptorligander til behandling af stofskifteforstyrrelser
ATE515504T1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
DE602005020313D1 (de) Bisaryl-sulfonamide
DE602007008868D1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
DK1848440T3 (da) Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
DK1725234T3 (da) Fremgangsmåder til behandling af lidelser eller sygdomme, der er forbundet med hyperlipidæmi og hyperkolesterolæmi, med minimering af bivirkninger
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
ECSP088314A (es) Moduladores de cannabinoides hexahidro-cicloheptapirazol
EP3856790A4 (en) ANTI-CD40 BINDING MOLECULES WITH MODIFIED CF DOMAINS AND THEIR THERAPEUTIC USES
FR2887785B1 (fr) Dispositif pour le traitement de substances organiques
WO2006116660A3 (en) Methods of inhibiting a gpr23
ATE416768T1 (de) Querverweise von tetrahydrothiopyrano-pyrazol- cannabinoidmodulatoren zu verwandten anmeldungen